- Home
- PYN vs RADX Comparison
PYN vs RADX Comparison
Compare PYN & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- RADX
- Stock Information
- Founded
- PYN 2002
- RADX 2021
- Country
- PYN United States
- RADX Australia
- Employees
- PYN N/A
- RADX N/A
- Industry
- PYN Investment Managers
- RADX
- Sector
- PYN Finance
- RADX
- Exchange
- PYN Nasdaq
- RADX NYSE
- Market Cap
- PYN 30.1M
- RADX 32.5M
- IPO Year
- PYN N/A
- RADX N/A
- Fundamental
- Price
- PYN $5.22
- RADX $4.25
- Analyst Decision
- PYN
- RADX Strong Buy
- Analyst Count
- PYN 0
- RADX 2
- Target Price
- PYN N/A
- RADX $13.50
- AVG Volume (30 Days)
- PYN 19.9K
- RADX 19.3K
- Earning Date
- PYN 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- PYN 5.07%
- RADX N/A
- EPS Growth
- PYN N/A
- RADX N/A
- EPS
- PYN N/A
- RADX N/A
- Revenue
- PYN N/A
- RADX $204,609.00
- Revenue This Year
- PYN N/A
- RADX N/A
- Revenue Next Year
- PYN N/A
- RADX N/A
- P/E Ratio
- PYN N/A
- RADX N/A
- Revenue Growth
- PYN N/A
- RADX N/A
- 52 Week Low
- PYN $4.84
- RADX $3.50
- 52 Week High
- PYN $6.60
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- PYN 44.30
- RADX N/A
- Support Level
- PYN $5.21
- RADX N/A
- Resistance Level
- PYN $5.37
- RADX N/A
- Average True Range (ATR)
- PYN 0.11
- RADX 0.00
- MACD
- PYN -0.00
- RADX 0.00
- Stochastic Oscillator
- PYN 3.26
- RADX 0.00
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.